It was surprising to observe that at hospital admission about 3% of patients with type 2 diabetes were treated with the new classes of anti-diabetes drugs, such as GLP-1 RA, DPP-4 inhibitors and SGLT2 inhibitors, despite their efficacy and safety profile even in the elderly people with type 2 diabetes. Here, SLC5A2 is linked to type 2 diabetes mellitus.